Core Viewpoint - Citius Pharmaceuticals Inc. has successfully closed a registered direct offering, raising approximately $6 million, with potential additional proceeds of up to $9.8 million from short-term warrants [1][3]. Group 1: Offering Details - The offering consisted of 4,920,000 shares of common stock priced at $1.22 per share, along with short-term warrants to purchase an additional 9,840,000 shares [1][3]. - The short-term warrants have an exercise price of $1.00 per share, are immediately exercisable, and will expire 24 months from the initial exercise date [1][3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support the commercial launch of LYMPHIR™, including milestone and regulatory payments, as well as general corporate purposes [3]. Group 3: Company Background - Citius Pharmaceuticals is focused on developing first-in-class critical care products, with LYMPHIR approved by the FDA for treating cutaneous T-cell lymphoma [6]. - The company also has a late-stage pipeline that includes Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief [6].

Core Viewpoint - Tempest Therapeutics, Inc. has entered into a definitive agreement for a registered direct offering of 739,000 shares at an offering price of $6.25 per share, expected to close around June 12, 2025, subject to customary conditions [1][2] Group 1: Offering Details - The offering is expected to generate approximately $4.6 million in gross proceeds before deducting fees and expenses [2] - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2] - The shares are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on January 27, 2025 [3] Group 2: Use of Proceeds - The net proceeds from the offering will primarily support a previously announced strategic alternative process, along with working capital and general corporate purposes [2] Group 3: Company Overview - Tempest Therapeutics is a clinical-stage biotechnology company focused on developing targeted and immune-mediated therapeutics for cancer treatment [5] - The company has a diverse portfolio of small molecule product candidates, ranging from early research to later-stage investigations in global studies [5]

Core Viewpoint - Acurx Pharmaceuticals, Inc. has successfully closed a registered direct offering of 2,745,000 shares at a price of $0.40 per share, along with a concurrent private placement of unregistered short-term warrants to purchase up to 8,235,000 shares at the same exercise price, aiming to raise approximately $1.1 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The registered direct offering involved 2,745,000 shares of common stock priced at $0.40 each, with a concurrent issuance of short-term warrants for 8,235,000 shares [1]. - The total gross proceeds from the offering were approximately $1.1 million before deducting fees and expenses [2]. - The warrants will be exercisable upon stockholder approval and will expire 24 months after such approval [1]. Group 2: Regulatory and Compliance Information - The shares were offered under a "shelf" registration statement filed with the SEC, which became effective on July 11, 2022 [3]. - The warrants and underlying shares have not been registered under the Securities Act and may not be sold in the U.S. without an effective registration statement or applicable exemption [4]. Group 3: Company Overview - Acurx Pharmaceuticals is focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections, particularly Gram-positive bacteria [6]. - The lead product candidate, ibezapolstat, is ready for Phase 3 trials for treating C. difficile infections, with plans for international clinical trials this year [6]. - The company's pipeline includes antibiotic candidates for various serious bacterial infections, including MRSA and drug-resistant Streptococcus pneumoniae [6].

RONKONKOMA, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- SUNation Energy, Inc. (Nasdaq: SUNE), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 17,391,306 shares of the Company’s common stock (or common stock equivalents in lieu thereof) Series A warrants to purchase up to an aggregate 17,391,306 shares ...